Zobrazeno 1 - 10
of 41
pro vyhledávání: ''
Autor:
Nicolas Freynet, Hervé Dombret, Daniel Lusina, Emmanuel Benayoun, Xavier Thomas, Estelle Guérin, Raphael Itzykson, Pascal Turlure, Claude Preudhomme, Laurène Fenwarth, Christine Terré, Aline Renneville, Elise Fournier, Thomas Boyer, Bouchra Badaoui, Isabel Garcia, Cécile Pautas, Thomas Cluzeau, Claude Gardin, Orianne Wagner-Ballon, Matthieu Duchmann, Juliette Lambert, Pierre Fenaux, Meyling Cheok, Bruno Quesnel
Publikováno v:
Leukemia. 36:656-663
The independent prognostic impact of specific dysplastic features in acute myeloid leukemia (AML) remains controversial and may vary between genomic subtypes. We apply a machine learning framework to dissect the relative contribution of centrally rev
Autor:
Courtney D. DiNardo, Lewis R. Silverman, Charles Cai, Claudia D. Baldus, Isabelle Genvresse, Eleni Lagkadinou, Neil Palmisiano, Walter Fiedler, Alice S. Mims, Michael Jeffers, Markus Wagner, Ioannis Mantzaris, Alexander E. Perl, Gary Wilkinson, Bingyan Wu, Christine Rentzsch, Eunice S. Wang, Timothy S. Pardee, Sebastian Schwind, Stefan Kaulfuss, Michael Heuser, Alwin Krämer
Publikováno v:
Leukemia
The mutant IDH1 (mIDH1) inhibitor BAY1436032 demonstrated robust activity in preclinical AML models, supporting clinical evaluation. In the current dose-escalation study, BAY1436032 was orally administered to 27 mIDH1 AML subjects across 4 doses rang
Autor:
Shaji Kumar, Carl Simon, Andreas Guenther, Fang Xiang, Sylvia Zhao, K. Gary Vanasse, Enrique M. Ocio, Yeow Tee Goh, Nicolas Hohmann, Sheeba K. Thomas, Marc S. Raab, Moshe Talpaz
Publikováno v:
Leukemia. 33:2924-2933
PIM447, a novel pan-PIM inhibitor, has shown preclinical activity in multiple myeloma (MM). In the multicenter, open-label, first-in-human study, patients with relapsed and/or refractory MM were enrolled to determine the maximum-tolerated dose (MTD)
Autor:
Rafael Fonseca, Sinto Sebastian, Luke Mountjoy, Greg J. Ahmann, Miguel Gonzalez-Velez, Tania Jain, Jeremy T. Larsen, Leif Bergsagel, Marlene Girardo, Talal Hilal
Publikováno v:
Leukemia. 34(11)
Autor:
Ruben A. Mesa, Moshe Talpaz, Olatoyosi Odenike, Catriona Jamieson, Srdan Verstovsek, Martha Wadleigh, Tomonori Uno, Brady L. Stein, Ellen K. Ritchie
Publikováno v:
Leukemia
NS-018 is a Janus-activated kinase 2 (JAK2)-selective inhibitor, targeting the JAK–signal transducer and activator of transcription (STAT) pathway that is deregulated in myelofibrosis. In this phase I, dose-escalation portion of a phase I/II study,
Autor:
Michael Pfreundschuh, Sebastien Rinaldetti, Markus Pfirrmann, Benjamin Hanfstein, Christian Dietz, Alice Fabarius, Rüdiger Hehlmann, Karsten Spiekermann, Christoph Scheid, Lothar Kanz, Susanne Saussele, Andreas Neubauer, Stefan W. Krause, C. Falge, E Oppliger-Leibundgut, Jolanta Dengler, Frank Stegelmann, Michael Lauseker, Joerg Hasford, Andreas Hochhaus, Lida Kalmanti, Ulrike Proetel, Martin C. Müller, L. Heinrich, Andreas Burchert
Publikováno v:
Leukemia. 29:1123-1132
Tyrosine kinase inhibitors (TKI) have changed the natural course of chronic myeloid leukemia (CML). With the advent of second-generation TKI safety and efficacy issues have gained interest. The randomized CML - Study IV was used for a long-term evalu
Autor:
Francesco Lo-Coco, Maria-Cristina Sauerland, Massimo Breccia, Sebastian Lehmann, Maria Pagoni, A. M. Nloga, Pau Montesinos, Bhuvan Kishore, Wolf-K. Hofmann, Lionel Adès, Safaa M. Ramadan, Anne Schmidt, E. Di Bona, Jean-Francois Lambert, David Grimwade, Jose D. González-Sanmiguel, Pierre Fenaux, A. J G Huerta, Eva Lengfelder, Miguel A. Sanz, Dennis Görlich, Bruno Cassinat
Publikováno v:
Leukemia. 29:1084-1091
In 2008, a European registry of relapsed acute promyelocytic leukemia was established by the European LeukemiaNet. Outcome data were available for 155 patients treated with arsenic trioxide in first relapse. In hematological relapse (n=104), 91% of t
Autor:
Delphine Rea, A.-L. Andreoli, Hervé Dombret, N Boissel, Emmanuel Messas, Tristan Mirault, Philippe Rousselot, Emmanuel Raffoux
Publikováno v:
Leukemia. 29:1206-1209
Usefulness of the 2012 European CVD risk assessment model to identify patients at high risk of cardiovascular events during nilotinib therapy in chronic myeloid leukemia
Autor:
Julio Delgado, Sílvia Beà, Alfons Navarro, Aneela Majid, Alejandra Martínez-Trillos, Julia Richter, Eva Giné, Cristina Royo, María Rozman, Itziar Salaverria, Reiner Siebert, Xose S. Puente, Armando López-Guillermo, Marta Aymerich, José I. Martín-Subero, Neus Villamor, Marta Kulis, Eva Maria Murga Penas, Magda Pinyol, Martin J. S. Dyer, Ciril Rozman, Carlos López-Otín, Mónica López-Guerra, Ana C. Queirós, Julia Kolarova, Sandrine Jayne, Nuria Russiñol, Elias Campo, Marcos González-Díaz, Gregorio Castellano, Dolors Colomer, Anke K. Bergmann, Guillem Clot
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
instname
Prospective identification of patients with chronic lymphocytic leukemia (CLL) destined to progress would greatly facilitate their clinical management. Recently, whole-genome DNA methylation analyses identified three clinicobiologic CLL subgroups wit
Autor:
Joerg Hasford, Lothar Kanz, Susanne Saussele, Mathias Hänel, Markus Pfirrmann, Christian Dietz, C. Falge, Cornelius F. Waller, Wolf-K. Hofmann, Ulrike Proetel, Susanne Schnittger, Benjamin Hanfstein, Jolanta Dengler, H. Einsele, Philipp Erben, Andreas Neubauer, Michael Pfreundschuh, Michael Kneba, Gabriela M. Baerlocher, Rüdiger Hehlmann, J. Schubert, Martin C. Müller, Alice Fabarius, Andreas Hochhaus, Michael Lauseker, Karsten Spiekermann, Stefan W. Krause, Valeria Shlyakhto, Frank Stegelmann
Publikováno v:
Leukemia. 28:1988-1992
Early assessment of response at 3 months of tyrosine kinase inhibitor treatment has become an important tool to predict favorable outcome. We sought to investigate the impact of relative changes of BCR-ABL transcript levels within the initial 3 month